Journal of Urology & Nephrology
Research Article
MicroRNA and messenger RNA As Potential Urinary Biomarkers in Prostate Cancer
Danarto R1, Astuti I2, Umbas R3, and Mubarika Haryana S4*
1Department of Surgery, Universitas Gadjah Mada, Indonesia
2Department of Pharmacology, Universitas GadjahMada, Indonesia
3Departmentof Urology, Universitas Indonesia, Indonesia
4Postgraduate Doctoral Program, UniversitasGadjahMada, Indonesia
*Address for Correspondence: Mubarika Haryana S, Postgraduate Doctoral Program, Faculty of Medicine, Universitas Gadjah Mada, Yogyakarta, Indonesia 55281, Indonesia; E-mail: Sofia.mubarika@gmail.com
Submission: 11 July, 2020;
Accepted: 5 October, 2020;
Published: 9 October, 2020
Copyright: © 2020 Danarto R, et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Introduction: Prostate Cancer (PCa) is the fifth leading cause of death world wide and these condmost common
cancerinmen. Studies to search for new biomarkers,especially with non-invasivemethods, are carried out, one of which is urinary biomarker as an early detection and predictors of PC aprognosis. microRNA (miRNA)
and messenger RNA(mRNA) has proven to have important roles in various oncogenic processes.
Material and methods: Urine samples collected from 145 patients
were examined,45 patients diagnosed with Benign Prostate Hyperplasia
(BPH) and 100 patients diagnosed with PCa.Urine samples were collected
from each patient and examined in the biomolecular laboratory.The
geneexpression were analyze dusing qPCR analysis using the qPCRCFX 96
thermocycler (Bio-Rad).
Results: The expression of miR-21-5p was higher in BPH group
compared to PC a groups, both non- metastatic and metastatic, with
p-values of 0.004 and 0.017, respectively. BPH showed the highest mRNA
expression of PDCD-4.
Conclusion: The overexpression of miR-21-5p shown in this study could
be a potential non-invasive diagnostic tool for patients with PCa. The lower
expression mRNA of PDCD-4 in non-metastatic compared to metastatic
PCa group could be potential prognostic biomarker in PCa.